Back to Search Start Over

Cancer-Related Fatigue

Authors :
F. Marc Stewart
Mario A. Eisenberger
Ashley Atkinson
Lynne I. Wagner
Barbara F. Piper
Charles S. Cleeland
Ann M. Berger
Amy P. Abernethy
William F. Pirl
Shirley Otis-Green
Phyllis Kaldor
Tracey O'Connor
Carmelita P Escalante
Andrea M. Barsevick
Victoria Mock
Pamela S. Hinds
Paul B. Jacobsen
Bernadine Cimprich
David Cella
Paul Sabbatini
Hope S. Rugo
Source :
Journal of the National Comprehensive Cancer Network. 5:1054
Publication Year :
2007
Publisher :
Harborside Press, LLC, 2007.

Abstract

Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. The problem, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than pain or nausea and vomiting, which, for most patients, can generally be managed with medications. For the most recent version of the guidelines, please visit NCCN.org

Details

ISSN :
15401413 and 15401405
Volume :
5
Database :
OpenAIRE
Journal :
Journal of the National Comprehensive Cancer Network
Accession number :
edsair.doi...........0e1bd7704e1d3baac15ff06f1f7d8eac